BioSpace News Archive

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that Dr. Stacy Lindborg, Co-Chief Executive Officer, and Chaim Lebovits, President and Chief Executive Officer, will participate in a fireside chat at the Maxim Group Healthcare Virtual Conference on Wednesday, June 21, 2023 at 9:00 a.m. Eastern Time.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-811 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab and chemotherapy met one of its dual primary endpoints of progression-free survival for the first-line treatment of human epidermal growth factor receptor 2 -positive advanced gastric or gastroesophageal junction adenocarcinoma.

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented new non-human primate data supporting the clinical advancement of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.

Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, announced that the Company will participate in a fireside chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST.

Navidea Biopharmaceuticals, Inc. announced that on June 14, 2023 it entered into an amendment to the Asset Purchase Agreement, dated November 23, 2016, between the Company and Cardinal Health 414, LLC, an affiliate of Cardinal Health, Inc.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

Stoke Therapeutics, Inc. announced that, effective on June 15, 2023, the company granted stock options to purchase an aggregate of 26,900 shares of common stock to 2 new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Navidea Biopharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2023.